2016 ACR/EULAR 幼年皮肌炎最小、中度与重大临床缓解标准
该国际协作项目基于IMACS和PRINTO核心组指标,通过分析312种定义并经验证,最终共识确立幼年皮肌炎联合分析连续模型总改善评分0-100,最小、中度、重大改善阈值分别为≥30、≥45、≥70,并在PRINTO和RIM试验中验证了区分治疗臂和医生评定的能力。
要点
- 总改善评分0-100基于核心组指标绝对百分比变化,阈值≥30、≥45、≥70分别对应最小、中度、重大改善。
- 在幼年皮肌炎队列中,最小改善敏感度89%、特异度91-98%;中度改善敏感度92-94%、特异度94-99%;重大改善敏感度91-98%、特异度85-86%。
- 该标准在PRINTO试验中可区分治疗臂(最小和中度改善p=0.009-0.057),在RIM试验中可显著区分医生对改善的评定(p<0.006)。
核心结论
- 幼年皮肌炎应答标准采用联合分析连续模型,基于核心组指标绝对百分比变化计算总改善评分0-100,以≥30、≥45、≥70分别定义最小、中度、重大改善。
研究设计与样本
- 国际肌炎评估与临床研究组(IMACS)与儿科风湿病国际试验组织(PRINTO)协作,分析312种基于核心组指标的定义,数据来自自然病史和联合分析调查,并在PRINTO泼尼松单药对比联合甲氨蝶呤或环孢素试验及RIM试验中验证,经共识会议用名义组技术确定标准。
主要发现
- 在幼年皮肌炎患者队列中,使用IMACS和PRINTO核心组指标时,最小改善的敏感度和特异度分别为89%和91-98%,中度改善为92-94%和94-99%,重大改善为91-98%和85-86%。
- 该标准在PRINTO试验中可区分治疗臂的最小和中度改善(p=0.009-0.057),在RIM试验中可显著区分医生对改善的评定(p<0.006)。
关键数值与推荐
- 总改善评分0-100,最小改善阈值≥30,中度改善阈值≥45,重大改善阈值≥70,基于核心组指标绝对百分比变化。
- 成人皮肌炎/多发性肌炎采用相同标准但改善阈值不同。
临床怎么用
- 临床可依据IMACS或PRINTO核心组指标的绝对百分比变化计算总改善评分,按≥30、≥45、≥70判定幼年皮肌炎的最小、中度与重大改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p=0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p<0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement.
引用
- Rider LG, Aggarwal R, Pistorio A, et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017. PMID: 28385804. doi:10.1136/annrheumdis-2017-211401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。